Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity and Jose Leiva 1 Division of Infectious Diseases, Clinica Universidad de Navarra, Pamplona, Spain; 2 Department of Internal Medicine, Clinica Universidad de Navarra, Pamplona, Spain; 3 Respiratory Medicine We present the first case of prolonged treatment with tedizolid after haematological toxicity and gastrointestinal intolerance with linezolid in a patient with pulmonary non-tuberculous mycobacterial infection.
A male patient in his seventies was diagnosed with a pulmonary infection caused by Mycobacterium avium intracellulare and Mycobacterium kansasii (American Thoracic Society/IDSA criteria). The antimicrobial susceptibility tests revealed that only ethambutol (MIC, 0.125 and 0.25 mg/L, respectively), clarithromycin (MIC, 0.5 and 0.008 mg/L), amikacin (MIC, 8 and 0.25 mg/L), cotrimoxazole (MIC, 0.032 and 0.001 mg/L) and oxazolidinones were active against both non-tuberculous mycobacteria. The therapeutic options available for our patient were limited to azithromycin, ethambutol and oxazolidinones given his previous gastrointestinal intolerance to clarithromycin and episode of renal toxicity with co-trimoxazole.
Oral combination therapy was administered sequentially with linezolid (600 mg twice daily), ethambutol (15 mg/kg once daily) and azithromycin (250 mg once daily). Linezolid MICs for M. avium intracellulare and M. kansasii were 0.008 and 0.25 mg/L, respectively.
Baseline laboratory tests revealed the following counts: haemoglobin (Hb) 13.5 g/dL, leucocytes 9.7%10 9 /L and platelets 265%10 9 /L. See Figure 1 . The patient experienced nausea and progressive anaemia since the beginning of the linezolid treatment; hence, linezolid was discontinued after 38 days of treatment (Hb 9.7 g/dL). At that time, his leucocyte and platelet counts were 5.6%10 9 /L and 209%10 9 /L, respectively. His nausea resolved immediately after discontinuing the linezolid treatment despite continuing treatment with ethambutol and azithromycin; however, his Hb levels continued to remain unchanged (9.5 g/dL) a week after discontinuing the linezolid treatment.
Tedizolid (200 mg once daily) was started after a 26 day washout period without linezolid, with the following counts: Hb 11.6 g/dL, leucocytes 5.1%10
9 /L and platelets 252%10 9 /L. Tedizolid MICs for M. avium intracellulare and M. kansasii were 0.002 and 4 mg/L, respectively. The patient tolerated the whole course of tedizolid (no nausea or other side effects). Hb levels remained stable for 42 days, although a subsequent decline lead to the necessary withdrawal of tedizolid after 58 days of treatment (Hb 9.6 g/dL). His leucocyte and platelet counts at the end of the treatment with tedizolid were 4.8% 10 9 /L and 284%10 9 /L, respectively. One week after discontinuing tedizolid, Hb was 10.1 g/dL.
Tedizolid is a more potent mitochondrial protein synthesis inhibitor than linezolid. 3, 4 However, although adverse events have been linked to mitochondrial toxicity, 5 tedizolid has a more favourable gastrointestinal and haematological profile than linezolid. 6 At therapeutic doses, tedizolid has greater in vitro potency against inhibition of mitochondrial protein synthesis, but of shorter duration, than that of linezolid. 5 Partial mitochondrial recovery and a lower cumulative effect explains, in animal studies, the fewer mitochondriopathic effects of tedizolid-particularly with long-term therapy 5 -the reduced impact on haematological parameters and the faster recovery from adverse effects. 7 Clinical tolerance was significantly better with tedizolid (i.e. no gastrointestinal symptoms). Myelotoxicity, which mainly took the form of anaemia, presented earlier with linezolid. Hb levels decreased immediately after initiating the linezolid treatment, but remained stable for 6 weeks with tedizolid. In our case, anaemia was the main cause of discontinuation for both drugs, although tedizolid could be continued for 58 days, 53% longer than linezolid (38 days), and the decline was smaller with tedizolid. Moreover, recovery of Hb was slower with linezolid, due to a greater cumulative effect of linezolid because of the higher dosing per day, relative to tedizolid. A decrease in leucocyte and platelet counts was only observed at the end of the therapy with linezolid; however, the patient did not experience leucopenia or thrombocytopenia, probably due to the fact that the treatment had previously been discontinued as a result of the onset of anaemia. No medical intervention, such as the administration of growth factors, erythropoietin or blood transfusions, had to be carried out as a result of the treatment with either oxazolidinone.
Lactate levels remained within the normal range, but higher values were observed at the end of treatment with linezolid (1.39 mmol/L) than with tedizolid (1.01 mmol/L). Finally, neurological toxicity was absent with both oxazolidinones.
Oxazolidinones do not require dosage adjustments for renal or hepatic dysfunction. However, myelotoxicity is greater in patients with severe renal impairment taking linezolid. 8 Renal function was decreased with linezolid, but not with tedizolid. A possible association with increases in linezolid plasma metabolite levels may contribute to increased toxicity, particularly in prolonged treatments. 9 The pharmacokinetics of tedizolid, however, remain unchanged, regardless of renal function. 10 Oxazolidinones are not considered in the standard treatment regimen for this mixed infection. However, according to a patient's antibiotic susceptibility, linezolid and tedizolid could be used as alternative drugs for the treatment of infections caused by rifampicin-resistant isolates of rapidly and slowly growing mycobacteria. In our case, the patient showed both clinical and radiological (chest CT scan) improvement after treatment with tedizolid.
In conclusion, in the long-term therapeutic use of oxazolidinones, tedizolid is a good alternative to linezolid in cases of inadequate clinical tolerance, myelotoxicity or renal failure secondary to increased toxicity. Figure 1 . Hb levels, platelet and leucocyte counts and creatinine clearance with linezolid and tedizolid. *Difference in Hb levels, platelet and leucocyte counts and creatinine clearance after treatment with linezolid and tedizolid. CL CR , creatinine clearance.
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